Brief: Frequency Therapeutics Receives Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
29/03/2023 22:02
March 29 (Reuters) - Frequency Therapeutics Inc
FREQ.O :
* FREQUENCY THERAPEUTICS INC - ON MARCH 28, CO RECEIVED
NOTICE OF
DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR
STANDARD FROM NASDAQ
Source text for Eikon: ID:
Further company coverage: FREQ.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Korro Bio
See all newsBrief: Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Korro Announces First Cohort Dosed In Phase 1/2 Clinical Trial (Anchor) For Krro-121
Brief: Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Korro Bio, Inc. reports results for the quarter ended June 30 - Earnings Summary
Korro Bio, Inc. expected to post a loss of $1.43 a share - Earnings Preview